The United Kingdom and the United States have hammered out a important trade agreement that will maintain zero import taxes on British pharmaceutical products entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to raise spending on drugs through the National Health Service (NHS). This move secures that duties on these vital goods will remain at zero for a duration of three years.
This deal is in response to previous statements to hike tariffs on patented drug products, with potential rates floated up to double the cost.
"This arrangement between the UK reinforces the international landscape for new treatments and establishes long-overdue equity to transatlantic pharmaceutical trade," a release declared.
Economic Impact
Drugs represent one of the the United Kingdom's biggest goods shipped to the US, which is clearly the biggest destination for major UK drugmakers.
Statistics reveal that in the 12 months to the end of last September, the UK shipped medicines valued at £11.1bn to the US. This amount represented nearly one-fifth of all goods exports in that span.
"This guarantee safeguards employment, increases investment and sets the stage for the UK to establish itself as a international leader for medical research," a government official stated.
Detailed British Pledges
The deal entails several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to double total public funding on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The amount drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, refunds topped twenty percent.
Broader Context
This agreement comes amid a protracted row between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were exacerbated by arguments that American customers were charged a premium for the same drugs than people in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while major expansions have been directed toward American operations.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its total funding over the last ten years.
